Mar 30 2010
The University of Illinois today announces that Chromatin, Inc., a
biotechnology company that has occupied space in the University's
Research Park since 2005 as part of the EnterpriseWorks incubator, is
expanding operations and graduating to a 5,000 square foot facility in
the Research Park. The expansion marks the company's continued
significant progress in commercializing its proprietary technology,
including mini-chromosomes which were originally developed at the
University of Chicago by company co-founder and CEO Daphne Preuss.
“Chromatin is graduating from our EnterpriseWorks
incubator where the Research Park provided laboratories, equipment and
greenhouse space”
Chromatin will transition to the newly constructed facility, which is
located in the "Graduation Building" of the Research Park, in April of
2010. With the larger laboratory and office space, the company will
continue to expand its R&D activities which enable the development of
new seed products and the delivery of multiple genetic traits in plants
through gene-stacking, while widening their focus to pursue new
applications, such as improved feedstocks targeting the bioenergy sector.
Avijit Ghosh, U of I VP of Technology and Business Development, said
Chromatin's commercialization success is a model for biotechnology
startups in Illinois. "Chromatin is graduating from our EnterpriseWorks
incubator where the Research Park provided laboratories, equipment and
greenhouse space," Ghosh said. "IllinoisVentures, the
university-affiliated venture capital firm, was an early Chromatin
investor. Also, The University of Illinois provided early support to
fund student employees to work as researchers for Chromatin, MBA
students to provide commercialization consulting, and entrepreneurship
support services with regular events and training."
Otto Folkerts, Director of Transgenic Programs and manager of
Chromatin's Champaign operation, said the University and Research Park
support enabled the company to focus on advancing its technology and its
business. "The EnterpriseWorks incubator has been the ideal place to
launch our R&D programs in crops such as corn, cotton and sugarcane,"
Folkerts said. "With the support of EnterpriseWorks, we've been
efficient with our resources and better able to focus our efforts on
innovation while developing our technology. By expanding the scale of
our operations within the Research Park, we can further develop our
existing programs and broaden our focus into new areas such as bioenergy
feedstocks."
Daphne Preuss, Chromatin's CEO, said "We are very pleased to be growing
our presence in the Champaign area and at the University's Research Park
location in particular. Our current expansion is a direct result of our
success in commercializing Chromatin's technology and successfully
attracting financing, both of which were greatly facilitated by the
University's resources, facilities and significant talent pool."
Chromatin was founded in 2000, is headquartered in Chicago and initially
opened an office/lab in the University of Illinois' EnterpriseWorks
incubator in 2005. Chromatin has successfully licensed its technology
through commercial agreements with leading agbiotech companies including
Syngenta, Monsanto, Dow AgroSciences, and Bayer CropScience, for
applications including corn, soybeans, cotton, sugarcane, and canola.
The company is now leveraging that success and its core technology base
by pursuing new value-added opportunities in the bioenergy feedstocks
market. Chromatin now employs over 30 people, including 11 in Champaign,
with plans for further increases in 2010.
Ghosh said he hopes other companies follow Chromatin's success model and
decide to remain in the park as their businesses grow. "We share in the
pride of Chromatin's success," Ghosh said. "Central Illinois and the
Midwest are a natural fit to grow the burgeoning 21st century
bioenergy sector given the strength of agricultural research and
industry."
Source University of Illinoiswww.illinois.edu